Latest news with #Hung
The Star
13 hours ago
- Entertainment
- The Star
Sammo Hung, 73, joins Douyin, posts three-generational family photo
Sammo Hung is finding ways to connect with his fans. Photos via China Press The 73-year-old Hong Kong martial arts superstar Sammo Hung has in recent years often been spotted using a wheelchair or cane when out and about. Whether at supermarkets in Shenzhen, China, or street markets in Sheung Shui, Hong Kong, he is frequently seen shopping on his own and enjoying a relaxed semi-retired life. In interviews, he has jokingly said that grocery shopping is a form of 'entertainment' for him – showing his love for life and his self-sufficiency. The Walled In star is also someone who keeps up with trends. Hung has officially joined the Chinese social media platform Douyin (the Chinese version of TikTok) with his own personal account. On June 5, he shared his first video on the platform, captioned humorously: 'Hello everyone, today I've finally 'fished' my way here,' playing on a pun in Mandarin for the word 'arrived.' In his second video, he shared edited clips from his classic films, accompanied by an inspiring voice-over. 'Failure is not frightening; it's the fear of failure that's truly daunting! Failure is just a temporary setback; perseverance is the eternal attitude.' (Translation via He also uploaded a video ahead of Father's Day (June 15), featuring his eldest son Timmy Hung wishing his followers a Happy Father's Day. The video includes a three-generational family portrait, with his wife, Joyce Godenzi, stealing the spotlight with her radiant beauty. The photo also features his two grandsons, Timmy's children with Janet Chow. As of June 8, it's reported Hung has 730,000 people following him on the platform.
Business Wire
21-05-2025
- Business
- Business Wire
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results from TRUST-I and TRUST-II, its pivotal Phase 2 clinical studies on the efficacy and safety of taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2025 Annual Meeting taking place May 30–June 3, 2025, in Chicago, Illinois. 'Taletrectinib is a highly selective, next-generation oral tyrosine kinase inhibitor, with the potential to expand what's possible for patients with ROS1-positive non-small cell lung cancer,' saidDavid Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. 'We look forward to presenting data from our pivotal TRUST-I and TRUST-II clinical studies, which further demonstrate the potential efficacy and safety of taletrectinib in patients across ethnicities and regions of the world. With a PDUFA date and potential approval by the U.S. FDA in just over a month, we are looking forward to hopefully bringing a truly meaningful new option to patients living with this disease.' Presentation Overview: Title: Presenter: Maurice Perol, Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France Date: Session Time: 1:30-4:30 p.m. CT Abstract Number: #8643 Location: Poster #123 The materials will be made available in the Publications section of Nuvation Bio's website after the session. To learn more about Nuvation Bio, visit Booth #28031 at the ASCO Annual Meeting. About Taletrectinib Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib is being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study. Based on results of the TRUST-I and TRUST-II clinical studies, the U.S. FDA has accepted and granted Priority Review to Nuvation Bio's NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval) and assigned a PDUFA goal date of June 23, 2025. The U.S. FDA previously granted taletrectinib Breakthrough Therapy Designation for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs, and Orphan Drug Designation for the treatment of patients with ROS1+ NSCLC and other NSCLC indications. In January 2025, China's NMPA approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib, a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit or follow the company on LinkedIn and X (@nuvationbioinc). Forward Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, our expectations regarding U.S. FDA approval and timing thereof, and taletrectinib's therapeutic potential in advanced ROS1+ NSCLC. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on May 7, 2025 under the heading 'Risk Factors,' and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.
Yahoo
20-05-2025
- Business
- Yahoo
SSGA's Hung on Fed Rate Cuts, Dollar Weakness
State Street Global Advisors President and CEO Yie-Hsin Hung says the Federal Reserve should cut interest rates three times in the second half of this year to support the weakening economy. Hung speaks with David Rubenstein for an episode of Bloomberg Wealth. This interview was recorded April 3 in New York. Sign in to access your portfolio
Business Times
19-05-2025
- Business
- Business Times
TransportBT: Singapore's surprising and thriving space industry
In the latest episode of TransportBT by The Business Times, host Derryn Wong dives deep into Singapore's space industry with Jonathan Hung, executive director, Office for Space Technology & Industry (OSTIn). The conversation delivers great insight into the current state and future potential of Singapore's space sector. Singapore's long history in space Contrary to popular belief, Singapore's involvement in space activities dates back several decades. Providing Wong with a quick history lesson, Hung points out that Singapore's first satellite ground station was established in Sentosa in 1971, and our first satellite was launched in 1998. Today OSTIn plays a pivotal role as Singapore's lead front for space activities. Hung explains that the office, having grown and evolved into its current form, is now divided into three main pillars - technology, industry, and international relations. OSTIn oversees satellite missions and supports a vibrant ecosystem of over 70 companies - fostering global partnerships. Key technologies and innovations Singapore excels in satellite subsystems, with significant investments in electronic stacks, hardware, and software. The country's strength in miniaturisation has enabled the development of smaller, more efficient satellites, crucial in the era of space democratisation spearheaded by entities like SpaceX. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Wong and Hung then turn their conversation to how space technologies directly benefit other industries in Singapore. For example, satellite communications which enhance maritime and aviation efficiencies - critical for Singapore's status as a global hub. Singapore's future in space exploration While Singapore may not have its own launch site due to land constraints, Hung does muse on the potential for the country to participate actively in space exploration missions. He believes that collaborations with other nations and companies will be key, particularly in areas like in-space robotics and advanced satellite communications. However for now, it is more earth based endeavours with the Earth Observation Initiative (EOI) which aims to tackle sustainability and humanitarian challenges through remote sensing satellite technology. This initiative underscores Singapore's commitment to using space technology for the greater good. Listen now to the conversation between Derryn Wong and Jonathan Hung which provides a comprehensive overview of Singapore's current achievements and future aspirations in the space sector. TransportBT is a podcast of BT Correspondents. Look out for the next episode featuring senior correspondent Leslie Yee on property matters. And if you have any thoughts or questions, feel free to reach out to us at btpodcasts@ --- Written and hosted by: Derryn Wong (derrynwong@ With Jonathan Hung, executive director, Office for Space Technology & Industry Edited by: Emily Liu & Claressa Monteiro Produced by: Derryn Wong, Emily Liu & Chai Pei Chieh A podcast by BT Podcasts, The Business Times, SPH Media --- Follow BT Correspondents: Channel: Amazon: Apple Podcasts: Spotify: YouTube Music: Website: Do note: This podcast is meant to provide general information only. SPH Media accepts no liability for loss arising from any reliance on the podcast or use of third party's products and services. Please consult professional advisors for independent advice. --- Discover more BT podcast series: BT Money Hacks: BT Podcasts: BT Market Focus: BT Branded Podcasts: BT Lens On:
Yahoo
16-05-2025
- Business
- Yahoo
State Street's Arm Partners With smallcase, Expands in India's Fintech
State Street Corporation's STT asset management arm, State Street Global Advisors ('SSGA'), has entered a strategic alliance with smallcase. The alliance aims to expand global market access for Indian investors and enhance SSGA's presence in India's fintech smallcase is a fintech platform that offers curated portfolios of stocks and ETFs, enabling retail investors to invest in diversified themes. Since its launch in 2016, the platform has facilitated transactions of over $16 billion and has established itself as a prominent player in India's digital investment market. The partnership will provide SSGA with a distribution opportunity for its SPDR ETFs by featuring them on smallcase's platform technology. This will enhance SSGA's global investment accessibility for Indian investors through technology-driven solutions. This partnership follows recent SSGA's participation in smallcase's $50 million Series D funding round, marking its first investment in India's asset and wealth management Hung, CEO of SSGA, stated, "India remains a priority market for SSGA, and we are impressed by the innovation smallcase brings to the investment ecosystem." Hung further said, "This relationship and investment aligns with our strategy of collaborating with leading wealth technology firms to enhance investor ease of access, choice and experience. Together with smallcase, we are excited to further the adoption of wealth-tech in India and improve individual investors' seamless access to global investment solutions.' Over the past six months, STT shares have gained 3.4% against the industry's decline of 6.7%. Image Source: Zacks Investment Research Currently, STT carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Last year, HSBC Holdings plc's HSBC India branch announced a strategic partnership with Bajaj Allianz General Insurance, one of the leading private general insurers in India. The aim of the bancassurance partnership is to offer Bajaj Allianz's comprehensive suite of insurance products and services to HSBC's vast customer base in India, based on a shared vision of financial inclusion and customer empowerment across the partnership between HSBC India and Bajaj Allianz leverages HSBC's well-established network and the latter's insurance expertise to provide tailored and innovative financial solutions to in October 2024, BlackRock Inc. BLK and India-based Jio Financial have obtained in-principle approval from the Securities and Exchange Board of India (SEBI) to act as co-sponsors and establish a mutual fund business in the granted the final approval after the fulfillment of certain requirements from both BLK and Jio Financial in the same month. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BlackRock (BLK) : Free Stock Analysis Report State Street Corporation (STT) : Free Stock Analysis Report HSBC Holdings plc (HSBC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
